Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630399 | 1.00 | ALDH1A1 (0.40) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL13370728 | 0.86 | ALDH1A1 (0.41) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL27651626 | 0.83 | ALDH1A1 (0.41) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL27641755 | 0.80 | ALDH1A1 (0.41) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL8701139 | 0.80 | PKM (0.38) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL3559527 | 0.76 | — | — | |
| SCHEMBL5086027 | 0.76 | — | — | |
| SCHEMBL27852103 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL27478065 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKML3MBTL1HTTLMNA | |
| SCHEMBL27585045 | 0.74 | PKM (0.39) | ALDH1A1PKML3MBTL1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | claimed |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | INDI MOLECULAR, INC. | 2024-05-30 | — | — | US | claimed |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | REGENERON PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | claimed |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2023-05-04 | — | — | US | claimed |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2022-11-29 | — | — | US | claimed |
| EP-3912641-A1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | Seagen Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| US-20210283210-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2021-09-16 | — | — | US | claimed |
| EP-3107557-B1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2021-06-09 | — | — | EP | claimed |
| US-10933112-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2021-03-02 | — | — | US | claimed |
| US-20200140487-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | REGENERON PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | claimed |
| WO-2015123679-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2015-08-20 | — | — | WO | claimed |
| CN-101903010-B | Topical compositions containing non-proteogenic amino acids and methods of treating skin | AVON PROD INC | 2014-11-26 | — | — | CN | claimed |
| EP-2559753-B1 | Microorganism having enhanced L-valine productivity and method for producing L-valine using the same | CJ CHEILJEDANG CORP (KR) | 2013-12-04 | — | — | EP | claimed |
| US-8465962-B2 | Microorganism having enhanced L-valine productivity and method for producing L-valine using the same | CJ CHEILJEDANG CORPORATION (KR) | 2013-06-18 | — | — | US | claimed |
| WO-2013024947-A1 | MICROORGANISM HAVING ENHANCED L-VALINE PRODUCTIVITY AND METHOD FOR PRODUCING L-VALINE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2013-02-21 | — | — | WO | claimed |
| US-20130045511-A1 | MICROORGANISM HAVING ENHANCED L-VALINE PRODUCTIVITY AND METHOD FOR PRODUCING L-VALINE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2013-02-21 | — | — | US | claimed |
| EP-2559753-A1 | Microorganism having enhanced L-valine productivity and method for producing L-valine using the same | CJ CheilJedang Corporation (KR) | 2013-02-20 | — | — | EP | claimed |
| CN-101903010-A | Topical compositions containing non-proteogenic amino acids and methods of treating skin | AVON PROD INC | 2010-12-01 | — | — | CN | claimed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140487-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | ARGLU1, NGLY1, VIP | ALDH1A1 4298/4885PKM 1361/4885L3MBTL1 38/4885 |
| US-20210283210-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | ALDH1A1 535/4885PKM 4701/4885L3MBTL1 1769/4885 |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | ALDH1A1 535/4885PKM 4701/4885L3MBTL1 1769/4885 |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | ARGLU1, NGLY1, VIP | ALDH1A1 4298/4885PKM 1361/4885L3MBTL1 38/4885 |
| US-10933112-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | ALDH1A1 535/4885PKM 4701/4885L3MBTL1 1769/4885 |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | ALDH1A1 535/4885PKM 4701/4885L3MBTL1 1769/4885 |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | ARGLU1, NGLY1, VIP | ALDH1A1 4298/4885PKM 1361/4885L3MBTL1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.